The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $49.32

Today's change+1.79 +3.77%
Updated October 16 4:02 PM EDT. Delayed by at least 15 minutes.
 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $49.32

Today's change+1.79 +3.77%
Updated October 16 4:02 PM EDT. Delayed by at least 15 minutes.

Novo Nordisk A/S Hits New 52-week High

Novo Nordisk A/S closed up sharply Monday, rallying (U.S.)$1.79 or 3.77% to (U.S.)$49.32 and setting a new 52-week high. Over the last five days, shares are unchanged, but are currently 1.06% below its 52-week high. This security has outperformed the S&P 500 by 4.70% during the last year.

Key company metrics

  • Open(U.S.) $49.32
  • Previous close(U.S.) $47.53
  • High(U.S.) $49.85
  • Low(U.S.) $49.18
  • Bid / Ask-- / --
  • YTD % change+37.53%
  • Volume3,327,318
  • Average volume (10-day)2,934,928
  • Average volume (1-month)2,215,503
  • Average volume (3-month)1,884,677
  • 52-week range(U.S.) $30.89 to (U.S.) $49.85
  • Beta0.62
  • Trailing P/E20.21×
  • P/E 1 year forward20.47×
  • Forward PEG2.47×
  • Indicated annual dividend(U.S.) $0.95
  • Dividend yield1.92%
  • Trailing EPS(U.S.) $2.44
Updated October 16 4:02 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+33.81%

Based on its net profit margin of 33.81%, Novo Nordisk A/S is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.03%Sector:Industry:

Latest Company News

View more News
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in $ millions unless otherwise notedJun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016
Revenue28,63828,45229,57227,537
Total other revenue--------
Total revenue28,63828,45229,57227,537
Gross profit24,22924,20124,65423,551
Total cost of revenue4,4094,2514,9183,986
Total operating expense15,25214,96218,36615,117
Selling / general / administrative7,6187,7009,0757,875
Research & development3,4143,2894,4703,458
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)------0
Other operating expenses, total-189-278-97-202
Operating income13,38613,49011,20612,420
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax12,64313,00410,94212,301
Income after tax9,95110,1568,6999,803
Income tax, total2,6922,8482,2432,498
Net income9,95110,1568,6999,803
Total adjustments to net income--------
Net income before extra. items9,95110,1568,6999,803
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items9,95110,1568,6999,803
Inc. avail. to common incl. extra. items9,95110,1568,6999,803
Diluted net income9,95110,1568,6999,803
Dilution adjustment000--
Diluted weighted average shares2,4842,5002,5172,531
Diluted EPS excluding extraordinary itemsvalue per share4.014.063.463.87
Dividends per sharevalue per share2.950.006.770.00
Diluted normalized EPSvalue per share4.014.063.463.87